AR001122A1
(es)
*
|
1995-03-06 |
1997-09-24 |
Akzo Nobel Nv |
Procedimiento de polímerizacion que utiliza una composición de peróxidos (co)polímero funcionalizadoobtenido por el proceso y uso de una composición de peróxidos
|
JP3991439B2
(ja)
*
|
1997-08-04 |
2007-10-17 |
東レ株式会社 |
繊維強化プラスチックおよび繊維強化プラスチックの成形方法
|
BR9814373A
(pt)
*
|
1997-12-22 |
2000-10-10 |
Arzo Nobel N V |
Combustìvel com caracterìsticas de ignição melhoradas, processo para preparação do mesmo, e, uso do mesmo
|
GB9809108D0
(en)
*
|
1998-04-30 |
1998-07-01 |
British Nuclear Fuels Plc |
Dimer
|
CA2347077A1
(en)
*
|
1998-10-16 |
2000-04-27 |
Akzo Nobel Nv |
Improved phlegmatization of cyclic ketone peroxides
|
JP2003527474A
(ja)
*
|
2000-03-16 |
2003-09-16 |
バーゼル、ポリオレフィン、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング |
ポリエチレンの製造方法
|
KR100819680B1
(ko)
|
2000-08-15 |
2008-04-04 |
아크조 노벨 엔.브이. |
트리옥세판 화합물
|
EP1186618A1
(en)
*
|
2000-09-08 |
2002-03-13 |
ATOFINA Research |
Controlled rheology polypropylene heterophasic copolymers
|
EP1216991A1
(en)
*
|
2000-12-22 |
2002-06-26 |
Akzo Nobel N.V. |
Transportable and safely packaged organic peroxide formulations comprising reactive phlegmatizers
|
BR0116560B1
(pt)
*
|
2000-12-29 |
2012-09-04 |
|
formulações de peróxido de metilpropil-cetona e seu uso em processos de cura de resinas de poliéster insaturado.
|
EP1219602A1
(en)
*
|
2000-12-29 |
2002-07-03 |
Akzo Nobel N.V. |
Methyl isopropyl ketone peroxide formulations and their use for curing unsaturated polyesters
|
US6762208B2
(en)
|
2001-10-01 |
2004-07-13 |
Air Products And Chemicals, Inc. |
Alkane diol foam controlling agents
|
EP1312617A1
(en)
|
2001-11-14 |
2003-05-21 |
ATOFINA Research |
Impact strength polypropylene
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
EP2364996B1
(en)
|
2002-09-27 |
2016-11-09 |
Xencor Inc. |
Optimized FC variants and methods for their generation
|
US7252784B2
(en)
*
|
2002-12-06 |
2007-08-07 |
Akzo Nobel N.V. |
Cyclic ketone peroxide formulations
|
CN1720241B
(zh)
*
|
2002-12-06 |
2010-10-06 |
阿克佐诺贝尔股份有限公司 |
环酮过氧化物配制剂
|
BRPI0407472B1
(pt)
*
|
2003-02-13 |
2015-07-07 |
Akzo Nobel Nv |
Composições de peróxidos de cetonas cíclicos estáveis ao armazenamento
|
EP1447404A1
(en)
*
|
2003-02-13 |
2004-08-18 |
Akzo Nobel N.V. |
Improved cyclic ketone peroxide compositions
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
JP5234734B2
(ja)
|
2004-06-01 |
2013-07-10 |
ジェネンテック, インコーポレイテッド |
抗体−薬物結合体および方法
|
DE102004029732A1
(de)
|
2004-06-21 |
2006-01-19 |
Basf Ag |
Hilfsmittel enthaltend Cyclohexanpolycarbonsäurederivate
|
CN101014619B
(zh)
|
2004-07-15 |
2010-11-03 |
赞科股份有限公司 |
优化的Fc变体
|
EP3088004B1
(en)
|
2004-09-23 |
2018-03-28 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
SI1850874T1
(sl)
|
2005-02-23 |
2014-01-31 |
Genentech, Inc. |
Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
|
US8334348B2
(en)
|
2006-03-03 |
2012-12-18 |
Akzo Nobel N.V. |
Process for the modification of biodegradable polymers
|
DK2383297T5
(da)
|
2006-08-14 |
2022-07-04 |
Xencor Inc |
Optimerede antistoffer rettet mod CD19
|
ES2372217T3
(es)
|
2006-09-12 |
2012-01-17 |
Genentech, Inc. |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de pdgfra, kit o kdr como marcador genético.
|
CN103432580A
(zh)
|
2007-03-02 |
2013-12-11 |
健泰科生物技术公司 |
基于低her3表达预测对her二聚化抑制剂的响应
|
EP3392273A1
(en)
|
2007-05-30 |
2018-10-24 |
Xencor, Inc. |
Methods and compositions for inhibiting cd32b expressing cells
|
SI2171090T1
(sl)
|
2007-06-08 |
2013-07-31 |
Genentech, Inc. |
Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
DE102009002652A1
(de)
*
|
2009-04-27 |
2010-10-28 |
BAM Bundesanstalt für Materialforschung und -prüfung |
Triacetontriperoxid und Diacetondiperoxid-Derivat, Verfahren zu ihrer Herstellung sowie ihre Verwendung
|
RU2012102056A
(ru)
*
|
2009-06-23 |
2013-07-27 |
ДАУ ГЛОБАЛ ТЕКНОЛОДЖИЗ ЭлЭлСи. |
Полипропилен с контролируемой реологией
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
KR20120123299A
(ko)
|
2009-12-04 |
2012-11-08 |
제넨테크, 인크. |
다중특이적 항체, 항체 유사체, 조성물 및 방법
|
RU2012132278A
(ru)
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
WO2011113802A2
(en)
|
2010-03-17 |
2011-09-22 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
JP2013523098A
(ja)
|
2010-03-29 |
2013-06-17 |
ザイムワークス,インコーポレイテッド |
強化又は抑制されたエフェクター機能を有する抗体
|
RU2012148699A
(ru)
|
2010-04-16 |
2014-05-27 |
Дженентек, Инк. |
Foxo3a как прогностический биомаркер для эффективности ингибитора пути киназы pi3k/акт
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
RU2013114352A
(ru)
|
2010-09-15 |
2014-10-20 |
Ф. Хоффманн-Ля Рош Аг |
Азабензотиазолы, композиции и способы применения
|
EP2637692A4
(en)
|
2010-11-12 |
2014-09-10 |
Scott & White Healthcare |
ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8
|
CA2817785A1
(en)
|
2010-11-19 |
2012-05-24 |
Toby Blench |
Pyrazolopyridines and pyrazolopyridines and their use as tyk2 inhibitors
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
FR2971510B1
(fr)
*
|
2011-02-10 |
2013-03-22 |
Arkema France |
Polymerisation radicalaire de l'ethylene amorcee par des peroxydes organiques a haute productivite
|
CA2827759C
(en)
|
2011-03-10 |
2018-10-16 |
Omeros Corporation |
Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
EP2742067A4
(en)
|
2011-08-12 |
2015-03-04 |
Omeros Corp |
MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
|
CN103889976A
(zh)
|
2011-08-12 |
2014-06-25 |
弗·哈夫曼-拉罗切有限公司 |
吲唑化合物、组合物及使用方法
|
WO2013041539A1
(en)
|
2011-09-20 |
2013-03-28 |
F. Hoffmann-La Roche Ag |
Imidazopyridine compounds, compositions and methods of use
|
CN102584782A
(zh)
*
|
2011-12-31 |
2012-07-18 |
北京理工大学 |
过氧化丙酮四聚体的制备方法
|
US20140170159A9
(en)
|
2012-03-08 |
2014-06-19 |
Ge Wei |
Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
|
US20130259867A1
(en)
|
2012-03-27 |
2013-10-03 |
Genentech, Inc. |
Diagnosis and treatments relating to her3 inhibitors
|
PL2885349T3
(pl)
*
|
2012-08-17 |
2018-10-31 |
Akzo Nobel Chemicals International B.V. |
Sposób utwardzania żywic termoutwardzalnych
|
AU2013304065B2
(en)
*
|
2012-08-17 |
2016-06-16 |
Akzo Nobel Chemicals International B.V. |
Process for curing thermoset resins
|
DE102013112821A1
(de)
|
2012-11-30 |
2014-06-05 |
Shell Internationale Research Maatschappij B.V. |
Kraftstoffzusammensetzungen
|
SG11201503897XA
(en)
*
|
2012-12-05 |
2015-06-29 |
Akzo Nobel Chemicals Int Bv |
Peroxide masterbatch based on bioresin
|
AR093664A1
(es)
*
|
2012-12-05 |
2015-06-17 |
Akzo Nobel Chemicals Int Bv |
Mezcla madre formada por un peroxido de cetona ciclico
|
ES2709724T3
(es)
*
|
2012-12-05 |
2019-04-17 |
Akzo Nobel Chemicals Int Bv |
Mezcla madre de peróxido basada en biorresina
|
AR093663A1
(es)
*
|
2012-12-05 |
2015-06-17 |
Akzo Nobel Chemicals Int Bv |
Lote maestro de peroxido basado en bioresina
|
ES2704661T3
(es)
*
|
2012-12-05 |
2019-03-19 |
Akzo Nobel Chemicals Int Bv |
Mezcla madre que comprende un peróxido cíclico de cetona
|
CN104822752B
(zh)
*
|
2012-12-05 |
2017-04-19 |
阿克佐诺贝尔化学国际公司 |
包含环酮过氧化物的母体混合物
|
WO2014096234A1
(en)
|
2012-12-21 |
2014-06-26 |
Shell Internationale Research Maatschappij B.V. |
Liquid diesel fuel compositions containing organic sunscreen compounds
|
CA2922925A1
(en)
|
2013-09-05 |
2015-03-12 |
Genentech, Inc. |
Antiproliferative compounds
|
WO2015049325A1
(en)
|
2013-10-03 |
2015-04-09 |
F. Hoffmann-La Roche Ag |
Therapeutic inhibitors of cdk8 and uses thereof
|
MY173652A
(en)
|
2013-10-24 |
2020-02-13 |
Shell Int Research |
Liquid fuel compositions
|
CN105814176B
(zh)
|
2013-12-16 |
2017-08-15 |
国际壳牌研究有限公司 |
液体燃料组合物
|
US20150190506A1
(en)
|
2013-12-17 |
2015-07-09 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
MX2016007972A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos para tratar canceres con antagonistas de union al eje pd-1 y taxanos.
|
EP3116865B1
(en)
*
|
2014-03-11 |
2017-11-15 |
Akzo Nobel Chemicals International B.V. |
Cyclic ketone peroxide composition
|
EP3632934A1
(en)
|
2014-03-31 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-ox40 antibodies and methods of use
|
MA39817A
(fr)
|
2014-03-31 |
2017-02-08 |
Hoffmann La Roche |
Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
|
EP2949732B1
(en)
|
2014-05-28 |
2018-06-20 |
Shell International Research Maatschappij B.V. |
Use of an oxanilide compound in a diesel fuel composition for the purpose of modifying the ignition delay and/or the burn period
|
FR3022251A1
(fr)
*
|
2014-06-13 |
2015-12-18 |
Arkema France |
Solvant organique pour peroxydes
|
EP3189046B1
(en)
|
2014-09-05 |
2020-08-26 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
JP2017529358A
(ja)
|
2014-09-19 |
2017-10-05 |
ジェネンテック, インコーポレイテッド |
がんの処置のためのcbp/ep300阻害剤およびbet阻害剤の使用
|
EP3204379B1
(en)
|
2014-10-10 |
2019-03-06 |
Genentech, Inc. |
Pyrrolidine amide compounds as histone demethylase inhibitors
|
AU2015343337A1
(en)
|
2014-11-03 |
2017-06-15 |
Genentech, Inc. |
Assays for detecting T cell immune subsets and methods of use thereof
|
EP3215536A1
(en)
|
2014-11-06 |
2017-09-13 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
CN107108613B
(zh)
|
2014-11-10 |
2020-02-25 |
基因泰克公司 |
布罗莫结构域抑制剂及其用途
|
SG10201807625PA
(en)
|
2014-11-17 |
2018-10-30 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3224258B1
(en)
|
2014-11-27 |
2019-08-14 |
Genentech, Inc. |
4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
|
WO2016106340A2
(en)
|
2014-12-23 |
2016-06-30 |
Genentech, Inc. |
Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
|
EP3240908A2
(en)
|
2014-12-30 |
2017-11-08 |
F. Hoffmann-La Roche AG |
Methods and compositions for prognosis and treatment of cancers
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
WO2016112251A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
CN107406414B
(zh)
|
2015-01-09 |
2022-04-19 |
基因泰克公司 |
作为用于治疗癌症的组蛋白脱甲基酶kdm2b的抑制剂的(哌啶-3-基)(萘-2-基)甲酮衍生物
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
CA2984003A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
US20170000885A1
(en)
|
2015-06-08 |
2017-01-05 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
KR20180011839A
(ko)
|
2015-06-08 |
2018-02-02 |
제넨테크, 인크. |
항-ox40 항체를 이용한 암의 치료 방법
|
AU2016280070B2
(en)
|
2015-06-17 |
2022-09-15 |
Genentech, Inc. |
Methods of treating locally advanced or metastatic breast cancers using PD-1 axis binding antagonists and taxanes
|
AU2016313263B2
(en)
|
2015-08-26 |
2021-02-04 |
Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) |
Condensed tricyclic compounds as protein kinase inhibitors
|
SG11201802774QA
(en)
|
2015-11-11 |
2018-05-30 |
Shell Int Research |
Process for preparing a diesel fuel composition
|
PL3400246T3
(pl)
|
2016-01-08 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
CN109154613A
(zh)
|
2016-04-15 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
用于监测和治疗癌症的方法
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
WO2017180581A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2017194554A1
(en)
|
2016-05-10 |
2017-11-16 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combinations therapies for the treatment of cancer
|
CN115028617A
(zh)
|
2016-05-24 |
2022-09-09 |
基因泰克公司 |
Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
EP3468997B1
(en)
|
2016-06-08 |
2023-09-13 |
Xencor, Inc. |
Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
MX2019003934A
(es)
|
2016-10-06 |
2019-07-10 |
Genentech Inc |
Métodos terapéuticos y de diagnóstico para el cáncer.
|
WO2018077976A1
(en)
|
2016-10-27 |
2018-05-03 |
Shell Internationale Research Maatschappij B.V. |
Process for preparing an automotive gasoil
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
FR3060011B1
(fr)
*
|
2016-12-08 |
2020-06-26 |
Arkema France |
Agent de durcissement pour durcir une resine de polymere
|
WO2018206729A1
(en)
|
2017-05-11 |
2018-11-15 |
Shell Internationale Research Maatschappij B.V. |
Process for preparing an automotive gas oil fraction
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
BR112020018457A2
(pt)
*
|
2018-03-13 |
2020-12-29 |
Nouryon Chemicals International B.V. |
Solução, formulação de peróxido, e processo de cura de resina radicalmente curável
|
CN108503885A
(zh)
*
|
2018-05-28 |
2018-09-07 |
广州印田新材料有限公司 |
一种含有酯类减敏剂的稳定的环酮过氧化物组合物
|
CN108586802A
(zh)
*
|
2018-05-28 |
2018-09-28 |
广州印田新材料有限公司 |
含有酯类减敏剂的稳定环酮过氧化物组合物的制备方法
|
BR112020026384A2
(pt)
|
2018-06-23 |
2021-03-30 |
Genentech, Inc. |
Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
|
BR112020025965A2
(pt)
|
2018-07-02 |
2021-03-23 |
Shell Internationale Research Maatschappij B.V. |
composições de combustível líquido
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
WO2020051099A1
(en)
|
2018-09-03 |
2020-03-12 |
Genentech, Inc. |
Carboxamide and sulfonamide derivatives useful as tead modulators
|
EP3853611A1
(en)
|
2018-09-19 |
2021-07-28 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for bladder cancer
|
EP3857230B1
(en)
|
2018-09-21 |
2023-06-07 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
PE20221449A1
(es)
|
2019-09-04 |
2022-09-21 |
Genentech Inc |
Agentes de union a cd8 y usos de los mismos
|
EP4034532A1
(en)
|
2019-09-26 |
2022-08-03 |
Exelixis, Inc. |
Pyridone compounds and methods of use in the modulation of a protein kinase
|
KR20220070237A
(ko)
|
2019-09-27 |
2022-05-30 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
|
FR3101349B1
(fr)
*
|
2019-09-27 |
2022-02-25 |
Arkema France |
Composition anhydre solide sous forme de poudre comprenant au moins un peroxyde organique, au moins un agent flegmatisant et au moins un liant et procédé préparation correspondant
|
CN114728936A
(zh)
|
2019-10-29 |
2022-07-08 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的双功能化合物
|
EP4055388A1
(en)
|
2019-11-06 |
2022-09-14 |
Genentech, Inc. |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
CN114728905A
(zh)
|
2019-11-13 |
2022-07-08 |
基因泰克公司 |
治疗性化合物及使用方法
|
WO2021119505A1
(en)
|
2019-12-13 |
2021-06-17 |
Genentech, Inc. |
Anti-ly6g6d antibodies and methods of use
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
JP2023523450A
(ja)
|
2020-04-28 |
2023-06-05 |
ジェネンテック, インコーポレイテッド |
非小細胞肺がん免疫療法のための方法及び組成物
|
CA3181820A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
US20210395366A1
(en)
|
2020-06-18 |
2021-12-23 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
US20230266322A1
(en)
|
2020-06-30 |
2023-08-24 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
|
CN115997123A
(zh)
|
2020-06-30 |
2023-04-21 |
国家医疗保健研究所 |
用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
JP2023536602A
(ja)
|
2020-08-03 |
2023-08-28 |
ジェネンテック, インコーポレイテッド |
リンパ腫のための診断及び治療方法
|
WO2022036146A1
(en)
|
2020-08-12 |
2022-02-17 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
CA3196277A1
(en)
|
2020-09-23 |
2022-03-31 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
EP4225443A1
(en)
|
2020-10-05 |
2023-08-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2022133345A1
(en)
|
2020-12-18 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
AU2022221124A1
(en)
|
2021-02-12 |
2023-08-03 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
WO2022178205A1
(en)
|
2021-02-19 |
2022-08-25 |
Exelixis, Inc. |
Pyridone compounds and methods of use
|
TW202313633A
(zh)
|
2021-05-25 |
2023-04-01 |
美商伊瑞斯卡公司 |
含硫雜芳族三環kras抑制劑
|
WO2022266206A1
(en)
|
2021-06-16 |
2022-12-22 |
Erasca, Inc. |
Kras inhibitor conjugates
|
WO2023018699A1
(en)
|
2021-08-10 |
2023-02-16 |
Erasca, Inc. |
Selective kras inhibitors
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033457A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|